Log in

MENS Jyong Biotech Ltd. NASDAQ · Taiwan

Jyong Biotech (MENS) news MENS going concern, IPO and Nasdaq notice news

Latest Jyong Biotech news

  1. Financings

    Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq

    Jyong Biotech, a Taiwan-based drug developer, priced 2,666,667 shares at $7.50 with Joseph Stone Capital, LLC as sole underwriter. Its lead candidate failed its primary endpoint in a pivotal U.S. trial, its auditor has raised going-concern doubt, and a Chinese court judgment puts about USD 19.4 million at stake.

Jyong Biotech annual financials

LineFY2025FY2024
Research and development$813,000$927,000
Net income (loss)-$4.7 million-$3.0 million
Cash from operations-$3.0 million-$3.6 million
Cash and equivalents$1.2 million$101,000

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $1.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Jyong Biotech

Has Jyong Biotech issued a going-concern warning?

Our latest story on this, dated Jun 18, 2025: "Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq". The story links the filing or release it is based on. Read the story.

When did Jyong Biotech go public?

Our latest story on this, dated Jun 18, 2025: "Jyong Biotech prices $20 million IPO of 2,666,667 shares at $7.50 on Nasdaq". The story links the filing or release it is based on. Read the story.

Has Jyong Biotech received a Nasdaq deficiency notice?

Our latest story on this, dated Apr 29, 2026: "Jyong Biotech files late-filing notice for its 2025 annual report on Form 20-F". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Jyong Biotech?

Jyong Biotech Ltd. trades under the ticker MENS on NASDAQ.

Where is Jyong Biotech listed?

Jyong Biotech Ltd. is listed on NASDAQ.

What is the SEC CIK of Jyong Biotech?

The SEC Central Index Key (CIK) for Jyong Biotech Ltd. is 1954488. Its filings are on SEC EDGAR.

How many shares does Jyong Biotech have outstanding?

76,027,667 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-05-15.

Which country or territory is Jyong Biotech listed under?

Our directory records Jyong Biotech Ltd. under Taiwan.

What does Jyong Biotech do?

Our directory classifies Jyong Biotech Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Jyong Biotech?

The ISIN recorded for Jyong Biotech Ltd. is KYG831161065.

Does aibio.space cover Jyong Biotech?

aibio.space lists Jyong Biotech Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Jyong Biotech incorporated?

SEC records list its state or country of incorporation as E9.

Is Jyong Biotech profitable?

Jyong Biotech Ltd. reported a net loss of $4.7 million for the fiscal year ended Dec 31, 2025, and used $3.0 million of cash in operations, per its annual report to the SEC.

How much does Jyong Biotech spend on research and development?

$813,000 in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Jyong Biotech have?

$1.2 million in cash at Dec 31, 2025, per its 20-F.

Investor discussion: Jyong Biotech

Members talk about Jyong Biotech (MENS). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Jyong Biotech, newest first. Each line links the filing it comes from.

  1. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source

  2. Distress

    Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source

  3. Financings

    Reported a financing. SEC Form 424B4. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:MENS on TradingView.

SEC filings and registration

SEC name
Jyong Biotech Ltd.
CIK
1954488
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
MENS (Nasdaq)
State or country of incorporation
E9
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
23F-3, NO.95, SEC. 1, XINTAI 5TH RD., NEW TAIPEI CITY
Phone
(8862) 27325205
Shares outstanding
76,027,667 as of 2025-12-31 (20-F filed 2026-05-15)

Recent filings (8-K and 6-K are the company's own announcements)

  • 20-F filed 2026-05-15
  • 6-K filed 2026-02-06
  • 6-K filed 2026-01-09
  • 6-K filed 2025-06-20

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Jyong Biotech Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MENS, recorded under Taiwan. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Jyong Biotech Ltd.
Ticker
MENS
Listing
NASDAQ
Country or territory
Taiwan
Business scope
Pharmaceuticals: Major
ISIN
KYG831161065
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.